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Abstract
Purpose We investigated the metabolic response of lung
cancer to radiotherapy or chemoradiotherapy by
18F-FDG
PET and its utility in guiding timely supplementary therapy.
Methods Glucose metabolic rate (MRglc) was measured in
primary lung cancers during the 3 weeks before, and 10–
12 days (S2), 3 months (S3), 6 months (S4), and 12 months
(S5) after radiotherapy or chemoradiotherapy. The associa-
tion between the lowest residual MRglc representing the
maximum metabolic response (MRglc-MMR) and tumor
control probability (TCP) at 12 months was modeled using
logistic regression.
Results We accrued 106 patients, of whom 61 completed the
serial
18F-FDG PET scans. The median values of MRglc at
S2, S3 and S4 determined using a simplified kinetic method
(SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g
for tumors with local control and 0.12, 0.16 and
0.19 μmol/min/g for tumors with local failure, and the
maximum standard uptake values (SUVmax) were
1.16, 1.33 and 1.45 for tumors with local control and
2.74, 2.74 and 4.07 for tumors with local failure (p<
0.0001). MRglc-MMR was realized at S2 (MRglc-S2)
and the values corresponding to TCP 95 %, 90 % and 50 %
were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and
0.70, 0.91 and 1.95 using SUVmax, respectively. Probability
cut-off values were generated for a given level of MRglc-S2
based on its predicted TCP, sensitivity and specificity, and
MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were deter-
mined as the optimum cut-off values for predicted TCP 80 %,
sensitivity 100 % and specificity 63 %.
Conclusion The cut-off values (MRglc ≤0.071 μmol/m-
in/g using the SKM and SUVmax ≤1.45) need to be
tested for their utility in identifying patients with a high
risk of residual cancer after standard dose radiotherapy
or chemoradiotherapy and in guiding a timely supple-
mentary dose of radiation or other means of salvage
therapy.
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Current standard radiotherapy administering a total dose
of 60 Gy in 30 fractions over a period of 6 weeks
(60 Gy/30 F/6 week) is still associated with local failure
rates of 40–45 % even in combination with cisplatin-
based concurrent chemotherapy in inoperable stage IIIA
and IIIB non-small-cell lung cancer (NSCLC) [1]. Thus,
there are about 40 % of patients who still have residual
cancer at the end of standard-dose radiotherapy and
chemotherapy, but we have no means of predicting
which ones. If a timely biomarker capable of detecting
residual cancer soon after standard radiotherapy were
available, individualized therapy providing a timely sup-
plemental dose of radiation or salvage surgery to
patients with residual cancer may be feasible while
patients with complete metabolic response implying
complete tumor control are saved from escalated radia-
tion doses beyond the standard dose and the associated
toxicities and cost.
Warburg described accelerated glucose transport and me-
tabolism in cancer, which is one of the most characteristic
biochemical changes occurring with malignant cellular
transformation [2]. A significant increase in the uptake of
2-deoxy-D-glucose and amino acids was reported by Issel-
bacher when cells were transformed in culture by polyoma-
virus and Simian vacuolating virus 40 (SV-40) [3]. The
glucose analog, 2-deoxy-D-glucose allows the measurement
of glucose metabolic rate (MRglc) that represents regional
glucose utilization through quantitative
18F-FDG PET [4].
Thus, biologic imaging could be useful in assessing meta-
bolic response of tumor cells to radiotherapy or chemora-
diotherapy [5–7]. It is also probable that such metabolic
changes will occur much sooner than changes in tumor size
[8, 9]. Therefore, changes in the metabolic status of cancer
cells may be an early biomarker for subsequent response of
the gross tumor including complete tumor control.
Radiation cell kill means loss of capacity for sus-
tained proliferation (loss of cell viability) as a conse-
quence of radiation-induced injury. Suit showed using
cinephotographic analysis of proliferative activity of
mammalian cells grown in vitro and subjected to single
doses of radiation that a cell may undergo one, two,
three, five, or even six divisions after irradiation before
the progeny of that radiation-killed cell undergo pykno-
sis and lysis [10].
We hypothesize that cessation of glucose metabolism
by tumor cells after radiotherapy or chemoradiotherapy
is a biomarker representing a cell’s inability to continue
its vital function, i.e., glycolysis. MRglc measured with
18F-FDG PET after radiotherapy or chemoradiotherapy
depends upon the number and metabolic activity of the
remaining tumor and host cells. No uptake indicates
with high probability that no living cells remain. Resid-
ual glucose uptake could reflect the presence of (a)
reproductively dead but metabolically intact tumor cells
(in full or part) admixed with (b) reproductively intact
cells, and (c) host cells. As the dose of fractionated
radiotherapy is increased, the number of reproductively
intact tumor cells decreases while the sum of both
tumor cell populations also decreases as reproductively
dead but metabolically intact cells undergo lysis with
time. There may not be a significant change in the host
cell population [11]. Therefore, it may be possible to
measure residual MRglc soon after radiotherapy or che-
moradiotherapy in the clinical setting using an in vivo
assay, which would represent the metabolic activities of
only two cell populations: residual tumor cells that are
metabolically alive but reproductively dead, and host
cells. Such a MRglc value measurable in vivo using
18F-FDG PET is likely to correspond to subsequent
complete tumor control.
We have reported following a prospective study that the
levels of residual MRglc quantified using
18F-FDG PET
14 days after preoperative radiotherapy or chemoradiother-
apy in patients with marginally operable stage IIB/IIIB
NSCLC is inversely correlated with the probability of his-
topathologic complete tumor control [8]. A similar observa-
tion was also subsequently reported by others [9, 12]. In this
follow-up prospective study, we wished to determine the
lowest level of residual MRglc representing the maximum
metabolic response (MRglc-MMR) after definitive radio-
therapy or chemoradiotherapy in lung cancer and investigate
its potential in predicting the probability of tumor control
(TCP) at 12 months. We also determined the optimum cut-
off value of MRglc-MMR based on its TCP, sensitivity
(probability of having residual tumor) and specificity (prob-
ability of having no residual tumor). Specific aims were:
1. To investigate the time-course of metabolic response,
measured with
18F-FDG PET, to radiotherapy or chemo-
radiotherapy in lung cancer and determine the earliest
time point at which MRglc-MMR is attainable.
2. To determine the correlation between the levels of
MRglc-MMR after radiotherapy or chemoradiotherapy
and subsequent complete tumor control at 12 months.
3. To determine the values of MRglc-MMR that corre-
spond to TCP ≥95 %, TCP 90 %, TCP 75 % and TCP
50 % at 12 months.
4. To determine the optimum cut-off value of MRglc-
MMR based on its predicted TCP, sensitivity and
specificity.
5. To determine correlation between MRglc measured us-
ing a simplified kinetic method (SKM) and standard
uptake value (SUV) before and after radiotherapy or
chemoradiotherapy in lung cancer.
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This prospective study was performed with the approval of
the Institutional Review Board of the Dana Farber Cancer
Institute and in accordance with an assurance filed with and
approved by the US Department of Health and Human
Services. Written informed consent was obtained from each
patient before enrollment.
Study design
The study design included serial measurement of MRglc
using the SKM and SUV, semiquantitative measurement of
18F-FDG uptake by PET in the primary lung cancers during
the 3 weeks before (S1), and 10–12 days (S2), 3 months
(S3), 6 months (S4) and 12 months (S5) after radiotherapy
or chemoradiotherapy. CT of the chest was also performed
at the time of the
18F-FDG PET studies.
This study was intended to provide the most cogent and
scientifically robust assessment of the association between
early
18F-FDG PET measurements and subsequent local
control. For this purpose, we used multiple criteria for the
determination of local tumor control or failure. Local con-
trol was determined with a combination of the following
criteria: (a) absence or decrease in MRglc to the level of
tumor bed background or to the uninvolved mediastinum
lasting a minimum of 12 months, and (b) no increase in size
of the primary tumor from the smallest sum of width, length
and height on study (this included the baseline sum if that
was the smallest on study) determine by serial CT scans for
a minimum of 12 months and beyond by the latest follow-up
CT scan. There was no time limit for detecting and defining
local failure during a patient’s survival time. Local recur-
rence detected even after 12 months of follow-up was
counted as local failure. Local failure was determined with
a combination of the revised response evaluation criteria in
solid tumors (RECIST) and PET response criteria in solid
tumors (PERCIST) on multiple restaging chest CT scans
and
18F-FDG PET scans for a minimum of 12 months [7,
13]. Biopsy was performed only if local tumor failure could
not be determined even with multiple sets of serial follow-
up
18F-FDG PET and chest CT scans specified during the
study protocol for a minimum follow-up period of
12 months.
Patients
Eligibility included inoperable stage I–III NSCLC and lim-
ited stage small-cell lung cancer (SCLC). Other criteria
included performance status (PS) 0 or 1, adequate general
condition for either chemoradiotherapy or radiotherapy with
curative intent, age ≥18 years, and absence of pregnancy.
Patients with bronchoalveolar carcinoma were excluded
from the study. Initial evaluation consisted of a complete
history and physical examination with special attention to
symptoms associated with primary or metastatic lung can-
cer; laboratory tests, including a complete blood cell count,
blood urea nitrogen, creatinine, and liver function tests, CT
of the chest and upper abdomen, whole-body
18F-FDG PET,
and brain MRI. When a PET/CT scanner became available,
the combined scans replaced both the chest CT and whole-
body
18F-FDG PET scans.
Treatments
Radiation dose schedules were as follows. In patients
with inoperable stage I NSCLC, a total dose of 70–
75 Gy was given in daily fractional doses of 2.5 Gy,
five fractions per week. In patients with inoperable
stages II/III NSCLC, a total dose of 63–6 6 . 6G yw a s
given in daily fractional doses of 1.8 Gy, five fractions
per week in combination with concurrent chemotherapy.
In patients with limited stage SCLC, a total dose of
63 Gy was given in 35 fractions, five fractions per
week [14]. Radiation therapy was administered as either
three-dimensional conformal radiation therapy or
intensity-modulated radiation therapy. Chemotherapy
consisted of concurrent platinum/etoposide (PE 50/50)
in patients with stage II/III NSCLC and good PS (PS 0
or 1). However, patients ≥70 years of age with PS 1 or
2 were treated with weekly carboplatin/paclitaxel during
radiotherapy and two additional cycles of high-dose
consolidation carboplatin/paclitaxel. In patients with lim-
ited stage SCLC, radiotherapy was combined with con-
current cisplatin/etoposide.
18F-FDG PET image acquisition and reconstruction
Whole-body
18F-FDG PET studies were performed us-
ing an ECAT HR+ PET scanner (Siemens/CTI). Patients
fasted for at least 6 h before scanning, and blood
glucose levels were measured and recorded immediately
before injection of
18F-FDG. Patients with uncontrolled
diabetes mellitus and fasting blood glucose >200 mg/dl
were excluded. A maximum dose of 333 MBq (9 mCi)
of
18F-FDG was injected intravenously. Images were
acquired in six or seven bed positions (10 min per
bed position) from the skull base to the mid-thigh
approximately 45 to 60 min after injection of
18F-
FDG. Transmission images were acquired using a rotat-
ing rod source with
68G ea n dw e r eu s e dt oc o r r e c tf o r
tissue attenuation. Images were reconstructed using seg-
mentation and emission subtraction with the ordered
subsets expectation maximization (OSEM) algorithm
(two iterations, eight subsets). A gaussian filter was
used for image reconstruction.
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Bothprimarytumorsandinvolvedregionallymphnodeswere
evaluatedusing1.0cm×1.0cmand0.5cm×0.5cmregionsof
interest (ROIs) on transaxial
18F-FDG PETimages. The ROIs
were drawn on multiple transaxial slices of tumor, and the
highest metabolic activity within the ROIs was measured
using both the SKM and SUV for determination of regional
glucose utilization. When little or no tumor-related radioac-
tivity was discernible by visual analysis (posttherapy studies),
the ROI was positioned on the basis of the CTscan data.
In an earlier study, we introduced and evaluated the SKM
as a simplified method for quantifying regional MRglc and
compared it with kinetic modeling (KM) and the widely
used semiquantitative method, SUV index, in 13 patients
with stage III NSCLC [15]. SKM measurements were found
to reliably predict KM measurements, and furthermore cor-
relations were better with the SKM than with SUV (the
coefficients of determination, R
2, were 0.96 and 0.53, re-
spectively, before chemoradiotherapy, and 0.94 and 0.71,
respectively, after chemoradiotherapy). Based on this find-
ing, we chose the SKM as the primary measurement method
in the current study. The lumped constant for the SKM
measurements was set at 1.0 and was assumed to be constant
over time. Details of the SKM have been reported by us
elsewhere [15]. Although the SUV index showed lower
coefficients of determination than the SKM when compared
with the gold standard KM in our prior study, we elected to
also determine SUVmax in this study for comparison with
the SKM for measuring metabolic response and its robust-
ness in predicting TCP and survival because of its method-
ological simplicity and availability.
For semiquantitative analysis of
18F-FDG uptake, SUV
parametric images were generated using computer software
developed in our laboratory. The SUVmax was measured
using the equation: SUVmax = Tcmax/(D/W), where Tcmax
is the maximum concentration of
18F-FDG in tumor
(microcuries per gram), D is injected dose of
18F-FDG
(microcuries) and W is body weight (grams) [16].
Statistical methods
The relationship between the levels of residual MRglc and
TCP was modeled using a logistic function [8]:
ln
TCP
1   TCP

¼ b0 þ b1 ln MRglc ðÞ
The logarithm of MRglc was used because the distribution
of MRglc values inoursample was approximatelylog-normal.
In our prior study, the level of MRglc after irradiation was
significantlyassociatedwithpathologictumor control,whilethe
level of MRglcbefore irradiation and the differencebetween the
levels before and after irradiation were not [8]. These
associations were studied again in the current investiga-
tion using univariate and multivariate analyses. The
relationship between the level of MRglc-MMR after
radiotherapy or chemoradiotherapy and TCP at 12 months
was obtained by fitting the logistic model to the col-
lected data. The MRglc level that corresponds to a
50 % chance of complete tumor control at 12 months
(MRglc-TCP 50 %) and the corresponding 95 % confi-
dence interval were estimated using Fieller’s theorem
[17]. In addition, MRglc-TCP 75 %, MRglc-TCP
90 % and MRglc-TCP 95 % were also estimated. The
goodness-of-fit model was evaluated using the Pearson
χ
2 test and the Hosmer-Lemeshow test. The measured
values of MRglc were compared between groups with
local tumor control and failure using the Mann-Whitney
test.
Receiver operating characteristic (ROC) curve analy-
sis was used to evaluate MRglc-MMR for its robustness
in predicting complete tumor control at 12 months after
radiotherapy or chemoradiotherapy [18]. In addition, we
created a model probability cut-off graph to determine
sensitivity (residual cancer) and specificity (no residual
cancer) at below and above the cut-off value of MRglc-
MMR, respectively. Thus, this graph provided a range
of cut-off values of MRglc-MMR for identifying
patients with a high probability of residual cancer and
offering supplemental radiotherapy or other means of
salvage therapy. The optimum cut-off value would dif-
ferentiate all patients with residual cancer requiring sup-
plemental therapy from patients in whom complete
tumor control has already been achieved so that such
additional therapy can be avoided in as many as
possible.
Multivariable analysis was also performed to deter-
mine the significance of age, gender, tumor volume and
stage, and tumor histology (SCLC vs. NSCLC) in pre-
dicting the degree of metabolic response. Backward
elimination was performed to eliminate nonstatistically
significant variables.
Overall survival was calculated according to the local
tumor control status at 12 months using the Kaplan-
Meier method and the log-rank test. In addition, we
set the reference point at 12 months (landmark method)
to avoid a known bias in favor of responders [19]. The
pretherapy log-transformed levels of MRglc (S1) deter-
mined using the SKM and SUVmax and the degree of
decline in MRglc between S1 and S2 were also corre-
lated with survival. A minimum sample size of 48
patients (tumors) was required to detect with 80 %
power an association between 100 % increase in MRglc
measured at the earliest time point with a 25 % increase
in the hazard of local failure at 1 year.
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Patient characteristics
We accrued 106 patients between January 2004 and August
2007. Patient demographics and tumor characteristics are
presented in Table 1.
To provide unequivocal and scientifically robust assess-
ment of the association between MRglc-MMR at the earliest
time point and subsequent local control, we excluded from
the analysis measurements that were incomplete or had
problematic interpretation. A total of 45 patients were ex-
cluded from the analysis for the following reasons: (a) early
death resulting from distant metastasis within 5 months
without local recurrence (n=10), (b) early death from failure
to thrive within 3 months and their local tumor control at
12 months could not be determined (n=5), (c) assessment of
local tumor control at 12 months was influenced by salvage
chemotherapy added for distant metastasis (n=2), (d) inter-
current disease (n=10), (e) withdrawal from study (n=5), (f)
symptomatic pneumonitis preventing accurate measurement
of MRglc-MMR at S2 (n=6), (g) granuloma hindering
accurate measurement of MRglc-MMR at S2 (n=2), and
(h) data corruption and technical difficulties in
18F-FDG
PET at S2 (n=5). Thus, the remaining 61 patients with 62
tumors were evaluable for the study goals.
The demographics and tumor characteristics of these 61
patients with 62 tumors were as follows: median age
70 years (range 44 to 90 years), 26 man and 35 women,
48 NSCLC and 14 SCLC, and 12 stage IA, 5 stage IB and
45 stage II/III. Of 62 tumors, 19 showed local failure and 43
showed complete control at 12 months. Local failure be-
came self evident with serial restaging
18F-FDG PET and
chest CT within 12 months in 18 of 19 patients, and fine
needle aspiration biopsy was necessary to confirm local
recurrence in only one patient.
Time-course of metabolic response to radiotherapy
or chemoradiotherapy
MRglc values of primary lung cancers at baseline and subse-
quent values of metabolic response measured with serial
18F-
FDG PETafter radiotherapy or chemoradiotherapy are shown
in Fig. 1. The median baseline MRglc value determined using
the SKM was 0.29 μmol/min/g and the median baseline
SUVmax was 6.9, and marked decreases were noted in re-
sponse to successful radiotherapy or chemoradiotherapy.
As shown in Fig. 1, the median values of MRglc at S1,
S2, S3, S4 and S5 determined using the SKM were, respec-
tively, 0.23, 0.05, 0.06, 0.07 and 0.07 μmol/min/g for
tumors with local control and 0.30, 0.12, 0.16, 0.19 and
0.21 μmol/min/g for tumors with local failure, and the
SUVmax were 6.15, 1.16, 1.33, 1.45 and 1.32 for tumors
with local control and 8.20, 2.74, 2.74, 4.07 and 3.87 for
tumors with local failure (p<0.0001, S2 through S5 for both
SKM and SUVmax). In patients with complete tumor con-
trol, residual MRglc reached its lowest value at S2 (MRglc-
S2) and was steady at S3 through S5, while in patients with
local failure it continued to rise after S2 reflecting steady
tumor progression with time. In addition, there was no
statistically significant difference in baseline values of
MRglc between those in whom complete tumor control
was and was not achieved at 12 months (p=0.90 and 0.06,
for SKM and SUVmax, respectively).
Maximum metabolic response after therapy and its
association with TCP
The observed tumor control status of 62 tumors at
12 months, their individual corresponding MRglc values
and SUVmax at S2, and their model predictions are shown
in Online Resource 1.
The relationship between residual MRglc-S2 and tumor
control status at 12 months was studied by dividing all 62
tumors into eight groups between the maximum and mini-
mum metabolic responders, as shown in Table 2. Complete
tumor control was achieved in 27 of 27 tumors with residual
MRglc-S2 ≤0.070 μmol/min/g. As residual MRglc in-
creased, the rate of complete tumor control declined. A
similar association between the degree of metabolic re-
sponse at S2 and the rate of tumor control was also observed
using SUVmax. No statistically significant correlation was
noted between the degree of decline in MRglc from baseline
to S2 and subsequent tumor control at 12 months (p=0.13).
Table 1 Patient demographics and clinical characteristics
Characteristic Value
Number of patients 106
Age (years)
Median 71
Range 44–90
Sex
Male 51
Female 55
Histologic type
a
NSCLC 89
SCLC 19
Tumor stage
a
I 26 (17 T1N0M0; 9 T2N0M0)
II 10 (4 T1-2N1M0; 6 T3N0M0)
IIIA 45 (40 T1-3N2M0; 5 T3N1M0)
IIIB 27 (27 T1-4N0-3M0)
aTwo patients had two separate primary tumors; thus, the total number
of tumors was 108.
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treatment was modeled using logistic regression [8]. The
logarithm of MRglc was used as an independent variable.
The maximum likelihood estimates of the model parameters
were determined: β0=−4.5 (95 % confidence interval,
CI, −7.3 to −1.6) and β1=−2.2 (95 % CI −3.4 to −1.0).
The MRglc-S2 values (μmol/min/g) corresponding to TCP
50 %, 75 %, 90 % and 95 % (with 95 % CI determined using
Fieller’s theorem) were 0.134 (95 % CI 0.10 to 0.22), 0.082
(95 % CI 0.052 to 0.11), 0.050 (95 % CI 0.031 to 0.080) and
≤0.036 (95 % CI 0.019 to 0.066), respectively, as shown in
Fig. 2a. The goodness-of-fit model was evaluated using the
Pearson chi-square test and the Hosmer-Lemeshow test:
Pearson chi-square 48.3 (53 degrees of freedom), probabil-
ity greater than chi-square 0.66, Hosmer-Lemeshow chi-
square 0.5.3 (data divided into ten groups based on the
predicted probability), probability greater than chi-square
0.73. According to both tests, the model fitted the data well,
as shown in Fig. 2b.
ROC curve and model versus probability cut-off
Metabolic response measured in terms of MRglc-S2 was
evaluated for its robustness in predicting TCP by ROC
curve analysis. As shown in Fig. 2c, the area under the
ROC curve (0.85) suggests good predictive power of the
model. A range of cut-off values of MRglc-S2 and their
corresponding TCP, sensitivity (probability of having resid-
ual tumor) and specificity (probability of having no residual
tumor) are shown in Table 3. MRglc ≤0.071 μmol/min/g by
SKM and SUVmax ≤1.45 were determined to be the likely
optimum cut-off values, and the rationale for this is given in
the Discussion.
Correlation between glucose metabolic rates measured
with SKM and SUVmax before and after therapies
The distributions of the SKM-determined values and SUV-
max were approximately log-normal using a logarithmic
Fig. 1 Time-course of metabolic tumor response measured with
18F-FDG PET and analyzed using SKM (a) and SUVmax (b) before and at
intervals after radiotherapy or chemoradiotherapy
Table 2 Residual MRglc by SKM and SUVmax at S2 (10–12 days after radiotherapy or chemoradiotherapy) divided into eight groups from low to
high levels and the corresponding tumor control status at 12 months in all 62 tumors
MRglc(μmol/min/gm) by SKM at S2 Tumor control at 12 months (%) SUVmax at S2 Tumor control at 12 months (%)
Group Range Group Range
≤0.030 0.013–0.023 5/5 (100 %) ≤0.62 0.39–0.62 5/5 (100 %)
≤0.050 0.032–0.050 16/16 (100 %) ≤1.15 0.63–1.15 16/16 (100 %)
≤0.070 0.054–0.069 6/6 (100 %) ≤1.35 1.16–1.35 4/4 (100 %)
≤0.090 0.072–0.086 5/10 (50 %) ≤1.93 1.36–1.93 8/12 (66 %)
≤0.110 0.093–0.107 3/5 (60 %) ≤2.21 2.01–2.21 3/5 (60 %)
≤0.130 0.116–0.130 3/6 (50 %) ≤2.74 2.22–2.74 2/6 (33 %)
≤0.150 0.133–0.145 2/3(66.6 %) ≤3.24 2.84–3.24 1/3 (33 %)
≤0.477 0.160–0.477 3/11 (27 %) ≤7.67 3.28–7.67 4/11 (36 %)
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maxof62tumorsin61patientswhocompletedthe study.The
correlation between SKM and SUVmax was strong with
coefficients of determination (R
2) values of 0.89, 0.89, 0.79,
0.88 and 0.90 at S1, S2, S3, S4 and S5, respectively.
Confounding factors that may affect MRglc 10–12 days
after therapy
There were only 14 SCLC, all ofwhich were locallycontrolled
at1year.Therewere17stageINSCLC(12stageIAtumorsof
1.0–3.0 cm, 5 stage IB tumors larger than 3.0 cm) and only 2
developed local failures. Therefore, it was not possible to
obtain separate results for SCLC and stage I NSCLC sub-
groups. However, a multivariable analysis of 1-year local
control using penalized logistic regression showed that SCLC
histology and tumor stage (either overall or tumor stage 1 vs.
higher) were not statistically significant predictors of 1-year
local control after adjusting for MRglc at S2. In addition, the
smallest value of MRglc by SKM in patients who were not
locally controlled (a parameter which affected the choice of
threshold SKM value) did not differ much between patients
with stage I and those with higher stages (0.072 vs.
0.076 μmol/min/g). On the other hand, regression without
the MRglc term showed thatboth SCLC and tumor stagewere
statisticallysignificantpredictorsof1-yearlocalcontrol.These
results suggest that SCLC histology and tumor stage are no
longer important for predicting 1-year local control after
MRglc (quantified either by SKM or in terms of SUVmax)
has been accounted for. Age (≥70 or <70 years) and gender
were not associated with higher values of MRglc-S2.
Fig. 2 Logistic model of TCP
as a function of residual MRglc
at S2 (a), Actual data points
superimposed on the regression
line (b), ROC curve showing
sensitivity versus one minus
specificity (c), and model
probability cut-off curves
showing sensitivity and
specificity values (d). The area
under the ROC curve was 0.85,
suggesting good predictive
power of the model
Table 3 Cut-off values of residual MRglc and SUVmax at S2 and
their corresponding TCP, sensitivity and specificity
Cut-off values of
MRglc (μmol/
min/g) by SKM
at S2
Cut-off
values of
SUVmax
a
at S2
TCP
(%)
b
Sensitivity
b Specificity
b
≤0.036 ≤0.92 95 100 % 19 %
≤0.050 ≤1.14 90 100 % 44 %
≤0.061 ≤1.32 85 100 % 53 %
≤0.071 ≤1.45 80 100 % 63 %
≤0.092 ≤1.75 70 74 % 74 %
≤0.134 ≤2.48 50 42 % 91 %
aSUVmax given as reference.
bValues based on MRglc determined using the SKM.
Fig. 3 C o r r e l a t i o nb e t w e e nM R g l cb yS K Ma n dS U V m a xa tS 1
through S5
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Neither the baseline value of MRglc (S1) nor the level of
decline in MRglc in response to therapy between S1 and S2
showed statistically significant association with survival.
However, using landmark method, patients who attained and
maintained local tumor control at 12 months demonstrated
longer overall survival than those with local failure (p=0.02).
Discussion
To address the high rate of local failure (40–45 %) and its
consequence on long-term survival associated with the cur-
rent standard radiation dose schedule, the RTOG (Radiation
Therapy Oncology Group) 0617 trial compared the standard
radiation dose schedule (60 Gy/30 F/6 week) with an esca-
lated dose schedule (74 Gy/37 F/7.4 week) in combination
with concurrent chemotherapy and with or without cituxi-
mab in patients with inoperable stage IIIA or IIIB NSCLC
[1, 20]. Overall survival rates at 12 months were 81 % with
60 Gy and 70 % with 74 Gy. Although this is an early result,
there was no difference between the standard dose and
escalated dose groups. Two new findings that we report
from this study may help develop a new paradigm for
therapy of patients with inoperable lung cancer. Therapy
can be personalized by offering a complementary dose of
radiation or other means of salvage therapy to patients with
ah i g hr i s ko fr e s i d u a lc a n c e rs o o na f t e rs t a n d a r dd o s e
radiotherapy and concurrent chemotherapy, while patients
with a complete metabolic response implying complete tu-
mor control (50 % of all patients) are saved from receiving
escalated radiation doses beyond the standard radiation dose
and the associated toxicities and cost.
Firstly, the earliest time-point at which the maximum met-
abolic response was found was 10 days after therapy. This is
contrary to the conventional recommendation that a restaging
18F-FDG PETscan be performed 3–4 months after therapy to
measure the maximum metabolic response. Since early sal-
vage therapy is likely more effective than late therapy in
tumors with high metastatic potential [21], this new finding
may have significant clinical implications. However, it is
prudent to investigate whether or not the maximum metabolic
response can be achieved even 1 week after radiotherapy or
chemoradiotherapy since planning of supplementary radio-
therapy and chemotherapy needs to take into account acceler-
ated cancer cell proliferation which occurs during the
treatment break.Ifmetabolicresponsedatafromthe latterpart
of the standard 6-week course of radiotherapy (i.e., the end of
week 4) and concurrent chemotherapy were to be utilized for
guiding patient selection and supplementary radiotherapy, the
treatment break can be avoided. However, such an approach
would have its own limitations because metabolic response
data obtained at the end of week 4 of standard radiotherapy
(40 Gy/20 F/4 week) may be less than optimum compared
with that obtainable after a full dose of standard radiotherapy
(60 Gy/30 F/6 week) for guiding personalized and supple-
mentary radiotherapy. Our results also showed no statistically
significantcorrelationbetweenthedegreeofdeclineinMRglc
frombaselinetoS2andsubsequenttumorcontrolat12months
(p=0.13).
Secondly, the cut-off values of MRglc-MMR, shown in
Table 3, indicate the potential utility of MRglc-MMR as a
surrogate bioimaging biomarker measurable noninvasively
10–12 days after therapy for advancing a new paradigm,
individualized and personalized therapy. If a cut-off MRglc
value of ≤0.071 μmol/min/g (SKM) or a SUVmax of ≤1.45
is chosen, it offers a sensitivity of 100 % and a specificity of
63 %, meaning that these values will identify all patients
with residual cancer for salvage therapy while also including
37 % of patients in whom complete tumor control has
already been achieved and who will receive additional ther-
apy. In this situation, supplementary radiotherapy will be
directed to a subvolume of the initial tumor outlined using a
residual MRglc threshold of ≥0.072 μmol/min/g or SUV-
max >1.45, and can be expected to be tolerated well. To the
best of our knowledge, this is also the first report of the
potential utility of residual FDG uptake cut-off values at S2
for developing personalized therapy based on metabolic
tumor response in patients with lung cancer. Nonetheless,
the robustness of these threshold values for identifying
patients with a high probability of residual cancer for sal-
vage therapy needs to be validated in the setting of a clinical
study before general use.
In the American College of Radiology Imaging Network
(ACRIN) 6668/RTOG 0235 study, the association between
SUVmax 12–16 weeks after therapy and local tumor control
was investigated in patients with stage III NSCLC [22].
SUVmax 12–16 weeks after therapy was, as expected, high-
ly correlated with local tumor control. Our study showed
that the correlation between metabolic response data and
local control rate was attainable as early as 10–12 days after
therapy.
Therapy-induced pneumonitis contributes to an increase
in residual MRglc after radiotherapy or chemoradiotherapy
and interferes with accurate assessment of metabolic tumor
response [23]. We excluded six patients from data analysis
because of an overt pneumonitis process.
We have evaluated the use of 3′-deoxy-3′-[
18F]-fluoro-
thymidine (
18F-FLT) PET in a cohort of patients showing an
increase in MRglc at S2 through S4 study suggesting either
local recurrence or inflammation [24].
18F-FLT PET was
able to distinguish local recurrence from local inflammation
correctly with a sensitivity of 83 % and a specificity of
89 %. Therefore,
18F-FLT PET might be useful for supple-
menting
18F-FDG PET in patients with a residual MRglc
Eur J Nucl Med Mol Imaging (2013) 40:832–841 839value of ≥0.072 μmol/min/g at S2 to improve the differen-
tiation of patients with local tumor control from those with
local failure. However, this hypothesis needs to be tested in
future studies.
There is a large body of data supporting the notion that a
supplementary dose of radiotherapy after a standard dose of
60 Gy/30 F/6 week would be effective in converting partial
response to complete tumor response leading to lasting
tumor control [25]. Nonetheless, it is important to take into
account accelerated cancer cell proliferation during a treat-
ment break and its adverse impact on local tumor control.
The strategy to overcome accelerated cancer cell prolifera-
tion would include accelerated delivery of a supplementary
dose of radiation and the use of concurrent chemotherapy. If
our study data were to be applied in future studies, we
recommend accelerated delivery of radiation by either a
twice-daily treatment schedule administering 3.0 Gy per
day as two fractions of 1.5 Gy with an interval of ≥6ho r
a hypofractionated schedule administering a daily fractional
dose of 3.0 Gy for 5 to 6 consecutive days including Satur-
day for a total supplementary dose of 15 to 18 Gy in 1 week
[26]. In addition, concurrent cisplatin-based chemotherapy
may be given with accelerated delivery of radiotherapy to
enhance local tumor control [27].
A limitation of this study was the absence of the kinetic
method, the “gold standard” that requires an 80-min dynam-
ic data acquisition and full kinetic analysis for measurement
of MRglc. However, such a method would be impractical in
a busy clinical service. Our prior study demonstrated that
MRglc measured with SKM had a very high correlation
with that measured by kinetic modeling [15]. Other inves-
tigators have also shown a significant correlation between
SKM, SUV indices and the kinetic method [28].
In conclusion, MRglc-MMR that can be obtained by
18F-
FDG PET 10–12 days after radiotherapyor chemoradiotherapy
may be a robust biomarker capable of predicting TCP in lung
cancer. The optimum cut-off values (MRglc ≤0.071 μmol/m-
in/g by SKM or SUVmax ≤1.45) need to be tested in clinical
studies for their potential to identify patients with a high risk of
harboring residual cancer soon after standard dose radiotherapy
or chemoradiotherapy who can be offered a supplementary
dose of radiation or other means of salvage therapy for im-
provement in local tumor control and survival.
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